Drug Reduces Biomarkers in Coronary Heart Disease

	Tweet

Darapladib reduces lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and other inflammatory markers in patients with coronary heart disease who are receiving Statins, according to a study in the April 29 issue of the Journal of the American College of Cardiology. A related study found that Statins have variable effects on oxidative stress markers in patients with High cholesterol.

In the first study, Emile R. Mohler III, M.D., of the University of Pennsylvania in Philadelphia and colleagues randomly assigned 959 patients with coronary heart disease or its risk equivalent who were receiving atorvastatin to one of three doses of darapladib or placebo. They found that darapladib inhibited Lp-PLA2 in a dose-dependent manner, with reductions in interleukin-6 and high-sensitivity C-reactive protein at the highest dose.

In the second study, Bonnie Ky, M.D., from the University of Pennsylvania and colleagues randomly assigned 120 patients with hypercholesterolemia to 40 milligrams pravastatin, 10 milligrams or 80 milligrams atorvastatin, or placebo. 

The researchers found that pravastatin led to a significant reduction in Lp-PLA2, while 10 milligrams atorvastatin led to a significant reduction in oxidized low-density lipoprotein. There were significant increases in oxidized phospholipids/apolipoprotein B-100 particle with pravastatin and 80 milligrams atorvastatin.

“Because inflammation plays a pivotal role in atherothrombosis and its clinical complications, inhibition of Lp-PLA2 might have promise as a suitable strategy to combat residual cardiovascular risk,” Wolfgang Koenig, M.D., of the University of Ulm Medical Center in Germany writes in an editorial.

The first study received support from GlaxoSmithKline. The second received a grant from Bristol-Myers Squibb. The author of the editorial has a relationship with GlaxoSmithKline.

ScoutNews, LLC

RELATED STORIES:
Scientists turn skin cells into beating heart muscle   Too many people get angioplasties, study suggests   New Blood Thinner May Lower Chances of Clots in High-Risk Heart Patients: FDA   Heart Damage After Chemo Linked to Stress in Cardiac Cells   What’s good or bad for the heart, may be the same for the brain   Warfarin in Heart Failure   Increased Sudden Cardiac Death Rate Among HIV Patients   Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease   Lack of basic evidence hampering prevention of sudden heart attacks in sport   Blacks Less Likely to Get Help on Scene After Cardiac Arrest: Study   Heart attack patients taken to PCI hospitals first treated faster   Cameron Health’s under-skin ICD safe, effective

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]